The Form 4 filing, a report of an insider's stock trades, was filed on November 12, 2026. It covers November 9 trades by Joshua B. Cohen, Amylyx's co-chief executive officer.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-09 |
| Date of Latest Transaction | 2026-11-09 |
| Buy/Sell | sell |
| Transaction Count | 2 |
| Shares Transacted | 100,000 |
| Price | $29.84 |
| Total Transaction Value | $2,983,677.77 |
| Insider | |
| Ticker Symbol | AMLX |
| Company | Amylyx Pharmaceuticals, Inc. |
| Insider Name | Cohen Joshua B |
| Insider Title | Co-Chief Executive Officer |
| Sector - Industry | Healthcare - Drug Manufacturers - Specialty & Generic |
| Holdings | |
| Total Shares Owned After Transaction | 3,513,123 |
| Position Size Change | 2.77% |
| Filing | |
| Filing Date | 2026-11-12 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were share sales, reported under transaction code S. The two transactions involved AMLX shares and are covered by one filing for one insider.
What was the average price of the transaction?
The average sale price was $29.84 per share, rounded to cents. This average covers both transactions. Separate prices for each sale are not available in the transaction details.
How did this transaction affect the insider's holdings?
After selling 100,000 shares, Joshua B. Cohen reported owning 3,513,123 shares. The sales accounted for 2.77% of his reported shares owned before the trades.
What's the total transaction value?
The two sales had a total value of $2,983,677.77, rounded to the nearest cent. This amount covers both transactions.
Are there any special circumstances around this transaction?
A Rule 10b5-1 trading-plan reference was identified for this filing. These plans set trading instructions in advance. The available details do not show which sales the reference covers. No footnote text or plan terms were provided, so the date the plan was set up and its trading schedule remain unknown.
For research purposes only; not investment advice.